ESTRELLA IMMUNOPHARMA, INC. Income (Loss) from Continuing Operations, Per Diluted Share
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Income (Loss) from Continuing Operations, Per Diluted Share of -$1.52 per share for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2022-03-29
- ESTRELLA IMMUNOPHARMA, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2021-09-30 was -$0.99.
- ESTRELLA IMMUNOPHARMA, INC. income (loss) from continuing operations, per diluted share for fiscal 2021 was -$1.52.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|---|
| 2021-12-31 | -$1.52 10-K · filed 2022-03-29 | ||
| 2021-09-30 | -$0.99 10-Q · filed 2021-11-10 | -$2.06 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |